SA-237 for neuromyelitis optica and neuromyelitis optica spectrum disorders

featured image
Therapeutic Areas: Neurology , Ophthalmology
Year: 2017

Neuromyelitis optica (Devic’s disease) is a rare autoimmune disorder (a condition where the immune system attacks itself). It is characterised by the inflammation of the nerve that leads from the eye to the brain, and the spinal cord. Symptoms consist of vision loss, loss of sensation, bladder dysfunction, weakness in limbs and paralysis and most patients tend to have relapsing attacks which can result in permanent brain damage if not treated soon enough.
Neuromyelitis optica is more common in females than males. Currently there are no licensed treatments for this condition, with treatments used for multiple sclerosis often being relied upon. SA- 237 is currently in phase III trials for the treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders. It is administered as an injection under the skin and is being developed as both a monotherapy and add-on therapy.